$90.54▲ 1.00 (1.12%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.0× debt-to-equity).
currently unprofitable (-45% margin).
Quality
1.5
Health
7.7
Growth
2.1
Valuation
6.4
Sentiment
7.2
Analyst Target
$123.22
▲ +36.1% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-17.4×
next 12 months est.
Market Cap
$22.9B
market capitalization
Div Yield
—
dividend yield
Profit Margin
-44.6%
net profit margin
Gross Margin
78.7%
revenue minus COGS
ROE
-6.7%
return on equity
Beta
1.32
vs S&P 500
52-Week Range
$80 — $124
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about BioNTech SE right now?
BioNTech SE's Q·Score is 4.7/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.0× debt-to-equity). Key area to monitor: currently unprofitable (-45% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for BNTX?
The consensus price target for BNTX is $123.22, based on ratings from 19 Wall Street analysts. This is 36.1% above the current price of $90.54. Price targets are forward-looking estimates and not guarantees of future performance.
Is BNTX overvalued or undervalued?
BioNTech SE (BNTX) scores in line with sector averages on valuation metrics. The consensus analyst price target of $123.22 is 36% above the current price.
When does BioNTech SE report its next earnings?
BioNTech SE's next earnings report is expected on approximately August 4, 2026.
What is BioNTech SE's profit margin?
BioNTech SE has a net profit margin of -44.6%, indicating the company is currently operating at a net loss. Its gross margin stands at 78.7%, indicating a high-margin business model.
Is BioNTech SE's revenue growing?
BioNTech SE is reporting revenue declining 35.4% year-over-year.
How much debt does BioNTech SE have?
BioNTech SE has a debt-to-equity ratio of 0.02×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 8.80×, indicating comfortable short-term liquidity.
Compare BNTX with any stock